Scholarlink

<p>In synucleinopathies, α-synuclein oligomers (OSyn) appear to be associated with neurodegeneration, neurotoxicity, and proinflammatory responses, even at low concentrations, suggesting their pivotal role in the pathogenesis of Parkinson’s disease (PD). We utilized a rat model of synucleinopathy induced by intrastriatal injection of OSyn, aiming to elucidate events preceding the formation of fibrillary α-syn aggregates. Electrophysiological assessments and behavioral assays revealed several early alterations in OSyn rats, evident as early as 12 weeks post-OSyn injection. These included mild and variable reduction of motor activity, anxiety-like behavior, impaired bidirectional striatal long-term synaptic plasticity, and diminished spontaneous excitatory neurotransmission in the striatum. Furthermore, p-α-syn aggregates were detected in the cortex but not in the substantia nigra (SN). Confocal microscopy analysis revealed reduced vesicular glutamate transporter 1 (VGluT1) expression at striatal glutamatergic terminals. Chronic administration of the ampakine Tulrampator to OSyn animals prevented impairment of long-term depression (LTD), spontaneous striatal neurotransmission, and VGluT1 levels. Tulrampator also ameliorated the anxiety-related behavioral phenotype, albeit without attenuating motor deficits, demonstrating its efficacy in mitigating early synaptic and emotional deficits induced by OSyn. These findings provide a basis for a novel drug treatment strategy aimed at mitigating or delaying early damage at cortico-striatal terminals induced by OSyn, thereby counteracting the pathophysiological processes underlying the onset of early non-motor symptoms in PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月29日

查看全文
  • Laura Bellingacci,
  • Miriam Sciaccaluga,
  • Alfredo Megaro,
  • Antonella Cardinale,
  • Jacopo Canonichesi,
  • Maria De Carluccio,
  • Roberta Mastrantonio,
  • Cinzia Costa,
  • Massimiliano Di Filippo,
  • Alessandro Usiello,
  • Maria Teresa Viscomi,
  • Paolo Calabresi,
  • Alessandro Tozzi

摘要

In synucleinopathies, α-synuclein oligomers (OSyn) appear to be associated with neurodegeneration, neurotoxicity, and proinflammatory responses, even at low concentrations, suggesting their pivotal role in the pathogenesis of Parkinson’s disease (PD). We utilized a rat model of synucleinopathy induced by intrastriatal injection of OSyn, aiming to elucidate events preceding the formation of fibrillary α-syn aggregates. Electrophysiological assessments and behavioral assays revealed several early alterations in OSyn rats, evident as early as 12 weeks post-OSyn injection. These included mild and variable reduction of motor activity, anxiety-like behavior, impaired bidirectional striatal long-term synaptic plasticity, and diminished spontaneous excitatory neurotransmission in the striatum. Furthermore, p-α-syn aggregates were detected in the cortex but not in the substantia nigra (SN). Confocal microscopy analysis revealed reduced vesicular glutamate transporter 1 (VGluT1) expression at striatal glutamatergic terminals. Chronic administration of the ampakine Tulrampator to OSyn animals prevented impairment of long-term depression (LTD), spontaneous striatal neurotransmission, and VGluT1 levels. Tulrampator also ameliorated the anxiety-related behavioral phenotype, albeit without attenuating motor deficits, demonstrating its efficacy in mitigating early synaptic and emotional deficits induced by OSyn. These findings provide a basis for a novel drug treatment strategy aimed at mitigating or delaying early damage at cortico-striatal terminals induced by OSyn, thereby counteracting the pathophysiological processes underlying the onset of early non-motor symptoms in PD.